Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors

Area of Science:

• Molecular Biology
• Cancer Genetics
• DNA Repair Mechanisms

Background:

• Mutations in SF3B1, a spliceosome component, are found in various cancers.
• SF3B1 is crucial for mRNA splicing, including genes involved in DNA damage response.
• Understanding SF3B1's role in DNA repair is vital for cancer therapy.

Purpose of the Study:

• To investigate the impact of SF3B1 mutations on DNA repair pathways.
• To determine if SF3B1 mutations confer sensitivity to DNA-damaging agents.
• To explore the therapeutic potential of targeting SF3B1-mutated cancers.

Main Methods:

• SF3B1 depletion and expression of the K700E mutant.
• Assessment of homologous recombination (HR) efficiency.
• Evaluation of sensitivity to ionizing radiation and chemotherapeutic agents, including PARP inhibitors.
• Analysis of R-loop formation, replication fork dynamics, and restart mechanisms.

Main Results:

• SF3B1 depletion compromises homologous recombination (HR) and is epistatic with BRCA1 loss.
• The SF3B1 K700E mutation impairs HR efficiency.
• SF3B1 K700E mutation increases sensitivity to ionizing radiation and chemotherapeutic agents, including PARP inhibitors.
• SF3B1 K700E induces R-loop formation, replication fork stalling, degradation, and defective restart.

Conclusions:

• Tumor-associated SF3B1 mutations induce a BRCA-like phenotype.
• This phenotype confers synthetic lethality with DNA-damaging agents and PARP inhibitors.
• Targeting SF3B1-mutated cancers with PARP inhibitors is a promising therapeutic strategy.